A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
This multicenter, randomized, double-blind study evaluated the efficacy, safety, and pharmacokinetics of atezolizumab (MPDL3280A) administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC). The safety of single-agent nab-paclitaxel has been determined in previous studies of participants with mBC and the safety data to date suggest that atezolizumab can be safely combined with standard chemotherapy agents.
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20007, United States
Jacksonville, Florida 32256, United States
St. Petersburg, Florida 33705, United States
Rochville, Maryland 20850, United States
Kansas City, Missouri 64132, United States
Vancouver, British Columbia V5Z 4E6, Canada
Grenoble, 38043, France
Halle, 06120, Germany
Heidelberg, 69120, Germany
München, 81675, Germany
Troisdorf, 53840, Germany
Naples, Campania 80131, Italy
Gunma, 373-8550, Japan
Hokkaido, 003-0804, Japan
D.F., 04980, Mexico
Warsaw, 02-781, Poland
Moscovskaya Oblast, Moscow Oblast 143423, Russia
Moscow, Moscow Oblast 105229, Russia
Moskva, Moscow Oblast 115478, Russia
Saint Petersburg, 197758, Russia
Istanbul, 34098, Turkey (Türkiye)
Sihhiye/Ankara, 06230, Turkey (Türkiye)